Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 14/20 | 0.73 |
| ▸ | HSPA1A | P0DMV8 | 12/20 | 0.73 |
| ▸ | GAPDH | P04406 | 8/20 | 0.73 |
| ▸ | POLB | P06746 | 7/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.73 |
| ▸ | MEN1 | O00255 | 6/20 | 0.73 |
| ▸ | BLM | P54132 | 5/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MASP2 | O00187 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 3/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.73 |
| ▸ | BRCA1 | P38398 | 3/20 | 0.73 |
| ▸ | RECQL | P46063 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | CD44 | P16070 | 2/20 | 0.73 |
| ▸ | MSN | P26038 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16706087 | 0.84 | PTPN7 (1.00) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL2116528 | 0.84 | PTPN7 (1.00) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL2808722 | 0.84 | PTPN7 (1.00) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL13186581 | 0.84 | PTPN7 (0.73) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL12768063 | 0.83 | PTPN7 (1.00) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL16872914 | 0.82 | PTPN7 (0.69) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL6215376 | 0.82 | POLB (0.77) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL16706084 | 0.82 | POLB (1.00) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL6217040 | 0.81 | CDC25B (0.68) | CDC25BPTPN7HSPA1AGAPDHPOLB | |
| SCHEMBL31492743 | 0.81 | PTPN7 (1.00) | CDC25BPTPN7HSPA1AGAPDHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249165-A1 | PDZ DOMAIN MODULATORS | UNIVERSITY OF COPENHAGEN (DK) | 2010-09-30 | — | — | US | claimed |
| EP-2164478-A2 | PDZ DOMAIN MODULATORS | University of Copenhagen (DK) | 2010-03-24 | — | — | EP | claimed |
| WO-2008148747-A2 | PDZ DOMAIN MODULATORS | UNIVERSITY OF COPENHAGEN (DK) | 2008-12-11 | — | — | WO | claimed |
| EP-1254118-B1 | SUBSTITUTED 1,2,3,4- TETRAHYDROQUINOLINE-2-CARBOXYLIC ACID DERIVATIVES | GRUENENTHAL GMBH (DE) | 2005-11-09 | — | — | EP | claimed |
| US-20040224969-A1 | Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds | GRUENENTHAL GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| US-6699877-B2 | TREATING PAIN, MIGRAINE, AND VARIOUS OTHER DISEASES | GRUENENTHAL GMBH (DE) | 2004-03-02 | — | — | US | claimed |
| US-20030087926-A1 | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives | GRUENENTHAL GMBH | 2003-05-08 | — | — | US | claimed |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20100249165-A1 | PDZ DOMAIN MODULATORS | UNIVERSITY OF COPENHAGEN (DK) | 2010-09-30 | — | — | US | disclosed |
| EP-2164478-A2 | PDZ DOMAIN MODULATORS | University of Copenhagen (DK) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008148747-A2 | PDZ DOMAIN MODULATORS | UNIVERSITY OF COPENHAGEN (DK) | 2008-12-11 | — | — | WO | disclosed |
| US-20040224969-A1 | Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds | GRUENENTHAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6699877-B2 | TREATING PAIN, MIGRAINE, AND VARIOUS OTHER DISEASES | GRUENENTHAL GMBH (DE) | 2004-03-02 | — | — | US | disclosed |
| US-20030087926-A1 | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives | GRUENENTHAL GMBH | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087926-A1 | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives | SDHA, CACNA1A, GRIN2C | CDC25B 2951/4885PTPN7 3463/4885HSPA1A 3371/4885 |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | PARP15, PAPSS1, PGA5 | CDC25B 3069/4885PTPN7 1733/4885HSPA1A 3534/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | CDC25B 2838/4885PTPN7 1941/4885HSPA1A 1479/4885 |
| US-20100249165-A1 | PDZ DOMAIN MODULATORS | PDLIM5, PSD, PDCD6IP | CDC25B 3261/4885PTPN7 740/4885HSPA1A 3109/4885 |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | PARP15, PAPSS1, PGA5 | CDC25B 3069/4885PTPN7 1733/4885HSPA1A 3534/4885 |
| US-20040224969-A1 | Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds | OPRK1, SDHA, GRIN2C | CDC25B 2583/4885PTPN7 4107/4885HSPA1A 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.